HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Andrews, G. A. Articles by Greenlaw, R. H. Search for Related Content PubMed PubMed Citation Articles by Andrews, G. A. Articles by Greenlaw, R. H.

Ga-67 Citrate Imaging in Malignant Lymphoma: Final Report of Cooperative Group

Gould A. Andrews^*, Karl F. Hubner and Robert H. Greenlaw

Oak Ridge Associated Universities, Oak Ridge, Tennessee

Correspondence: For reprints contact: Karl F. Hübner, Medical and Health Sciences Div., Oak Ridge Associated Universities, P.O. Box 117, Oak Ridge, TN 37830.

ABSTRACT

In a large cooperative study of Ga-67 uptake in non-Hodgkin's malignant lymphoma, 76% of untreated patients showed positive uptake in one or more lesions. The percentage of known individual lesions seen on scan was significantly lower; thus, negative findings at any one site may have much less significance than positive findings. After treatment, the number of lesions seen decreases sharply, but the role of Ga-67 in evaluating response to therapy is uncertain, especially in view of the fairly large number of lesions undetectable before therapy. Histologic type plays a role in Ga-67 uptake. Large lesions are much more effectively detected than small ones. In spite of numerous false-negative results, Ga-67 scanning is a useful method in evaluating the extent of untreated disease and the presence of lesions posttherapy.

FOOTNOTES

^* Present address: Div. of Nuclear Medicine, University of Maryland Hospital, Baltimore, MD 21201.

Present address: Dept. of Diagnostic Radiology, Marshfield Clinic, Marshfield, WI 54449.